Pharvaris N.V. (PHVS) News
Track canonical SquawkNews coverage tagged to PHVS, Pharvaris N.V.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Pharvaris Reports Q2 2026 Financial Results
Pharvaris reports second quarter 2026 financial results and provides business update
EARNINGS | Aug 12, 2026, 10:50 AM UTC
L
PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
EQUITY | Jul 28, 2026, 11:29 AM UTC
L
Pharvaris announces publication of review article on bradykinin
Pharvaris announces publication of review article on bradykinin
EQUITY | Jul 22, 2026, 10:53 AM UTC
L
IBM downgraded, Cava upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: Morgan Stanley upgraded Cava Group
EQUITY | Jul 15, 2026, 01:34 PM UTC
L
PHVS Initiated Overweight W/$55.00 PT at Wells Fargo
PHVS Initiated Overweight W/$55.00 PT at Wells Fargo
EQUITY | Jul 15, 2026, 11:47 AM UTC
L
PHVS new Overweight W/ $55 PT @ WELLS
PHVS new Overweight W/ $55 PT @ WELLS
EQUITY | Jul 15, 2026, 11:36 AM UTC
L
Sector Update: Healthcare Stocks Mixed Premarket Monday
() -- Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.3%. Novartis (NVS) stock was down more than 1% a
MNA | Jul 06, 2026, 01:18 PM UTC
L
Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target A
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to re
REGULATION | Jul 06, 2026, 10:53 AM UTC
L
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to tre
REGULATION | Jul 06, 2026, 10:50 AM UTC